About
Our Company

Management

Board of Directors

Scientific Advisory Board

Partners

About TScan

TScan is a clinical-stage biotechnology company dedicated to changing lives by developing safe and effective T-cell therapies for patients.
Our Approach
Our Science

How We’re Different

Hematologic Malignancies

Solid Tumors

Autoimmunity

Our Approach

Our approach is based on the premise that conventional T cells provide the most effective way to fight cancer, and that by genetically reprogramming T cells with highly effective, naturally occurring T cell receptors (TCRs), we can harness the power of the human immune system to deliver life-changing therapies to patients.
Pipeline
Our Pipeline

Hematologic Malignancies Program

Solid Tumor Program

Pipeline

We are advancing a robust pipeline of TCR-T therapy candidates derived from our proprietary platform to treat patients with heme malignancies and solid tumors
Platform
TargetScan

ReceptorScan

SafetyScan

T-Integrate Cell Engineering

Platform

Our proprietary platform is designed to discover anti-cancer TCRs from patients with exceptional responses to immunotherapy.
Publications
Investors and Media
For Patients
Patient Overview

Hematologic Malignancies

Solid Tumors

Expanded Access Policy

For Patients

We are committed to bringing new immunotherapies to cancer patients.
Careers

Unleash immunity

TScan is a clinical-stage biotechnology company dedicated to creating life-changing T-cell therapies for patients by unleashing the untapped potential of the human immune system

How We're Different

News

TScan Therapeutics to Participate in Upcoming Investor Conferences

News

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

News

Unleash immunity

TScan Therapeutics to Participate in Upcoming Investor Conferences

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference